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consequently to a decreased level of
NMF, measurement of NMF could
improve classification of AD pheno-
types. Identification of this measurable
physical parameter as a marker of FLG
status could enable more targeted pre-
vention of AD in susceptible individuals.
Measurement of the NMF phenotype
in particular by in vivo Raman spectro-
scopy, is much less demanding
then genotyping. This initial study
shows some highly promising results.
Sensitivity and specificity of this meth-
od will be further investigated in
larger, well-defined study groups to
explore its potential usefulness in clini-
cal practice.
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TO THE EDITOR
Allergic contact dermatitis (ACD) is a
frequent T-cell-mediated inflammatory
skin disease in response to skin expo-
sure to non-protein chemicals, called
haptens. Development of ACD pro-
ceeds in two phases (Saint-Mezard
et al., 2004). The sensitization (afferent)
phase, induced by the migration of
hapten-loaded skin dendritic cells
(DCs) to draining lymph nodes, leads
to the priming of hapten-specific effec-
tor T cells. The elicitation (efferent)
phase, generated on skin re-exposure
to the same hapten, induces the recruit-
ment of T cells into the skin resulting in
ACD through IFN-g production and
cytotoxicity toward keratinocytes.
Allergic contact dermatitis is a major
public health concern in industrialized
countries, and there is an urgent need
for tests allowing for detection of
potentially allergenic compounds manu-
factured by industries (Diepgen and
Kanerva, 2006; Williams et al., 2006).
Predictive testing for the sensitizing
properties of haptens has been tradi-
tionally carried out in guinea pigs and
mice (Gerberick et al., 2007; Maurer,
2007). More recently, alternative
in vitro methods have been developed
to test the ability of haptens to prime
naive peripheral blood T cells. These
assays, referred to as primary sensiti-
zation assays, consist of an auto-
logous mixed DC–lymphocyte reaction
(MDLR) using hapten-loaded DCs as
antigen-presenting cells and normal
human peripheral blood leucocytes
(PBLs) as responding cells. In vitro
priming of hapten-specific T cells was
usually assessed by cell proliferation
Abbreviations: ACD, allergic contact dermatitis; DC, dendritic cell; MDLR, mixed DC–lymphocyte
reaction; PBL, peripheral blood lymphocyte
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Table 1. In vitro T-cell priming to contact sensitizers is improved in the absence of CD25+ cells
Cell proliferation Cytokine secretion
Undepleted MDLR CD25+ T-cell-depleted MDLR Undepleted MDLR CD25+ T-cell-depleted MDLR
3[H]Thymidine incorporation
(c.p.m.±SD)
3[H]Thymidine incorporation
(c.p.m.±SD) IFN-c secretion IFN-c secretion
Chemical
Experiment
no.
Hapten-pulsed
MDDC
Unpulsed
MDDC SI
Hapten-pulsed
MDDC
Unpulsed
MDDC SI
Hapten-pulsed
MDDC
Unpulsed
MDDC SI
Hapten-pulsed
MDDC
Unpulsed
MDDC SI
TNBS 1 1,337±1,707 2,561±860 0.5 756±369 90±45 84 24 29 0.8 41 4 10.1
(1,000mgml1) 2 1,163±620 368±11 3.2 2,192±894 502±216 4.4 6 6 1.0 37 7 5.3
3 12,447±2,204 4,760±586 2.6 17,786±3,066 1,385±1,418 12.8 76±2 50±22 1.5 397±62 89±48 4.5
4 3,137±733 1,963±337 1.6 6,424±264 740±529 8.7 43±6 13±4 3.3 72±22 16±6 4.5
5 1,863±755 706±134 2.6 8,123±390 338±157 24 102±8 89±17 1.1 269±51 73±22 3.6
6 8,643±708 3,133±406 2.8 6,168±1,002 1,630±307 3.8 41 31 1.3 197 32 6.2
7 1,495±611 1,245±355 1.2 7,560±2,136 315±102 24 10±3 9±11 1 22±11 7±3 3
8 6,769±1,208 4,195±649 1.6 6,070±1,845 2,722±723 2.2 15 16 0.9 225 11 20.5
9 4,655±1,242 2,253±787 2.1 7,449±1,178 2,068±1,272 3.6 137 68 2 89 70 1.3
10 1,141±464 363±78 3.1 9,798±262 3,297±1,246 3 29±7 23±17 1.3 519±188 130±4 4
11 1,125±115 1,086±262 1 744±452 432±418 1.7 144 155 0.9 19 14 1.4
12 ND — 1,049±802 102±43 10.3 ND — 137 44 3.1
13 ND — 5,653±1,381 1,193±547 4.7 ND — 222 20 11.1
FITC 5 650±218 706±134 0.9 1,036±488 338±157 3.7 87±33 117±47 0.7 222±29 202 1.1
(300mgml1) 6 2,930±883 3,133±406 0.9 2,836±350 1,630±307 1.7 16 31 0.5 52 32 1.6
8 5,859±2,035 4,195±649 1.4 6,800±2,034 2,722±63 2.5 9 16 0.6 41 11 3.7
HCA 1 663±228 2,561±860 0.25 499±71 90±45 5.5 ND — ND —
(130–400mgml1) 2 407±152 368±11 1.1 570±227 502±216 1.1 5 6 0.8 3 7 0.4
7 1,871±615 1,245±355 1.5 275±71 315±102 0.9 10±1 9±11 1 7 7±3 1
9 2,335±514 2,253±787 1 4,202±1,181 2,068±1,272 2 88 68 1.3 153 70 2.2
10 766±64 364±78 2.1 11,237±3,951 3,287±1,246 3.4 25±20 23±17 1.1 218±91 130±4 1.7
11 1,219±349 1,086±263 1.1 851±626 432±418 2 136 155 0.9 12 14 0.8
12 ND — 156±43 102±43 1.5 ND — 31 44 0.7
13 ND — 1,581±964 1,193±547 1.3 ND — 18 20 0.9
DMSO 5 666±149 706±134 0.9 248±57 338±157 0.7 100±21 119±47 0.8 203±68 202 1
(1,000mgml1) 6 3,052±383 3,133±406 1 1,733±485 1,630±307 1.1 10 31 0.3 22 32 0.7
8 5,547±2,381 4,195±649 1.3 2,650±347 2,722±63 1 14 16 0.9 5 11 0.5
SLS 1 1,091±125 2,561±860 0.4 172±108 90±45 1.9 ND — ND —
(4–40 mgml1) 2 366±201 368±11 1 939±230 502±216 1.9 ND — ND —
12 ND — 125±34 102±43 1.2 ND — 17 44 0.4
HCA, a-hexylcinnamaldehyde; MDDC, monocyte-derived dendritic cells; MDLR, mixed dendritic cell–lymphocyte reaction; ND, not determined; PHA,
phytohemagglutinin; SI, stimulation index; SLS, sodium lauryl sulfate; TNBS, 2,4,6-trinitrobenzene sulfonic acid.
A total of 4–8 105 hapten-pulsed and unpulsed MDDCs (1,000mgml1 TNBS, 300 mgml1 FITC, 130–400mgml1 HCA, 1,000 mgml1 DMSO, or
4–40 mgml1 SLS) were cultured for 5–7 days with 2 105 autologous lymphocytes (depleted or not depleted in CD25+ cells). The proliferative responses
were assayed by 3[H]thymidine incorporation (1 mCi per well) for the last 8 hours of culture. INF-g secretion was measured by ELISA in the supernatant of the
cultures restimulated for the last 15 hours with 2 mgml1 PHA. Lymphoproliferation and INF-g secretion induced by hapten-pulsed MDDC were compared
with those that were obtained with unpulsed MDDC, and results are expressed as SI: response recorded for hapten-pulsed MDDC/response recorded for
unpulsed MDDC. Results are considered positive for SI42 (bold values).
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and/or T-cell cytokine production at the
end of the 5- to 7-day culture (Krasteva
et al., 1996; Rustemeyer et al., 1999;
Rougier et al., 2000). Although some
strong experimental haptens were able
to activate T cells in these primary
sensitization assays, the magnitude of
the T-cell response was routinely low
and the results were poorly reproduci-
ble. One possible reason for the poor
sensitivity of these assays may be the
low frequency of hapten-specific T-cell
precursors in normal individuals
(Rougier et al., 2000). Alternatively,
in vitro priming of T cells may be
repressed by naturally occurring
CD4þCD25þ regulatory T cells
(nTreg), which comprise up to 5% of
the peripheral CD4þ T-cell pool and
which are known to downregulate both
the afferent and efferent phases of ACD
(Vocanson et al., 2006). In this respect,
studies on contact hypersensitivity and
oral tolerance to strong and weak
haptens have shown that acute deple-
tion of CD4þ T cells or CD25þ
T cells in normal C57BL/6 mice results
in a dramatic increase in the number of
hapten-specific IFN-g-producing T cells
in lymph nodes draining the sensitiza-
tion site (Dubois et al., 2003; Vocanson
et al., 2006). Therefore, we postulated
that in vitro T-cell priming to haptens
might be more efficient if CD25þ cells
were absent from the responding T-cell
population. The data presented here
confirm this hypothesis and show that
depletion of PBLs in CD25þ cells
increases the magnitude of hapten-
specific T-cell sensitization in vitro.
A classical human autologous MDLR
was used. DCs were generated from
6-day cultures of monocytes (isolated
from peripheral blood of healthy
donors) in complete RPMI medium
supplemented with 10% fetal calf
serum and recombinant human GM-
CSF and IL-4 (R&D Systems, Lille,
France). Monocyte-derived DCs were
then incubated for 10minutes with the
strong/moderate haptens TNBS (2,4,6-
trinitrobenzene sulfonic acid) and FITC,
with the clinically relevant weak fra-
grance allergen HCA (a-hexylcinnamal-
dehyde) or with the non-sensitizers
DMSO and sodium lauryl sulfate. After
washing, haptenated DCs were co-
cultured for 5–7 days with either un-
depleted or CD25þ -cell-depleted PBLs
from normal human donors. Depletion
of PBLs in CD25þ T cells was
achieved using anti-CD25 mAb-coated
microbeads and negative-selection col-
umns (Myltenyi Biotech, Bergish Glad-
bach, Germany) and routinely resulted
in 90% depletion of CD4þCD25þ T
cells. Priming of hapten-specific T cells
during the MDLR was determined by (i)
analysis of cell proliferation following
addition of 3[H]thymidine for the last
8 hours of culture and (ii) titration of
IFN-g production in culture superna-
tants after addition of a sub-mitogenic
dose of phytohemagglutinin (PHA) for
the last 15 hours of culture, as described
previously (Vocanson et al., 2006).
Results were expressed as a stimulation
index corresponding to the ratio of
values recorded with hapten-pulsed
versus unpulsed MDDC. Results show
that depletion of naive PBLs in CD25þ
T cells improves the sensitivity of the
primary sensitization assay and allows
for detecting the sensitizing properties
of chemicals with moderate (FITC)/
weak (HCA) allergenic properties. In-
deed, classical primary autologous
MDLR, that is, using undepleted PBLs
as responding cells, resulted in (i) a
moderate proliferative response to
TNBS (in 6/11 experiments) with IFN-g
production in only 2/11 experiments;
(ii) no proliferative response and IFN-g
production to FITC; and (iii) prolifera-
tive response to HCA in only 1/6
experiments without IFN-g production.
In contrast, depletion of naive PBLs in
CD25þ T cells increased the sensitivity
of the MDLR inasmuch as (i) a strong
T-cell proliferation and IFN-g produc-
tion in response to TNBS was observed
in almost all (12/13) experiments and
(ii) mild but significant proliferative
responses were obtained in 2/3 experi-
ments (with IFN-g production in 1/3
experiments) for FITC and 4/8 experi-
ments (with IFN-g production in 1/7
experiments) for HCA; (iv) the non-
sensitizers, DMSO and sodium lauryl
sulfate, did not induce any PBL prolifera-
tion or IFN-g production. Therefore,
depletion of PBLs in CD25þ T cells
allows for optimal in vitro priming of
T cells against contact sensitizers but not
against xenobiotics devoid of sensitizing
properties (DMSO, sodium lauryl sulfate).
In conclusion, this study confirms
the hypothesis that regulatory cells
may prevent the priming/expansion of
specific T-cell precursors and further
suggests that in vitro primary sensitiza-
tion assays using CD25þ -cell-depleted
PBLs could be sensitive methods to
test for the potential immunogenic
properties of haptens, especially those
endowed with weak sensitizing proper-
ties, such as fragrances and dyes
(Vocanson et al., 2006) (Table 1).
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TO THE EDITOR
Cyclin-dependent kinase inhibitor 2A
(CDKN2A/p16) is a high-penetrance,
autosomal-dominant melanoma predis-
position gene (Cannon-Albright et al.,
1992; Kamb et al., 1994) and mutations
of this tumor suppressor are associated
with a markedly increased risk of
melanoma (Goldstein and Tucker,
1995; Kefford et al., 1999). CDKN2A/
p16 activity is required for melanocyte
senescence in vitro (Gray-Schopfer
et al., 2006). Pathogenic mutations
have been discovered in approximately
10% of Utah melanoma pedigrees
(Eliason et al., 2006). We recently
reported in the Journal the results of a
longitudinal follow-up study of mem-
bers of a Utah melanoma-prone kin-
dred with a temperature-sensitive
V126D CDKN2A/p16 mutation. Muta-
tion carriers accumulated significantly
more melanocytic nevi over a 15-year
interval than non-carrier family mem-
bers or spouse control subjects (Florell
et al., 2004). Moreover, carrier subjects
possessed more nevi on warm body
regions, such as the head, neck, and
trunk (Florell et al., 2005). These
findings suggest that in addition to
conferring melanoma susceptibility,
CDKN2A/p16 mutation contributes to
nevus development and distribution. To
this end, we hypothesized that (1)
pedigree members with a non-tempera-
ture-sensitive pathogenic CDKN2A/p16
mutation would possess more melano-
cytic nevi and have a larger nevus
density than non-carrier subjects; and
(2) a temperature-sensitive nevus dis-
tribution would not be identified. To
obtain additional evidence regarding
the effect of a different CDKN2A/p16
mutation on nevus formation, we stu-
died a second Utah melanoma pedigree
with a promoter-region (G-34T)
CDKN2A/p16 mutation in the 50 un-
translated region that results in a false
initiation site with reduced translation
of wild-type CDKN2A/p16 (Liu et al.,
1999) and segregates with melanoma
susceptibility in melanoma pedigrees
(Liu et al., 1999; Harland et al., 2000).
This study was approved by the
University of Utah Institutional Review
Board (Utah IRB no. 7916) and was
conducted according to the Declaration
of Helsinki principles utilizing informed
written consent. Thirty-one members
of the G-34T pedigree and 13 spouse
control subjects participated approxi-
mately 12 years earlier in this follow-
up examination. All subjects were
examined by the same dermatologist
(LJM) for the initial and follow-up
studies. Neither the participants nor
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Figure 1. Comparison of TNN and TND in V126D and G-34T CDKN2A/p16 kindreds.Mutation carriers
in both kindreds have larger TNN and TND than non-carrier and spouse control subjects. V126D
mutation carriers had larger TNN and TND than G-34T mutation carriers, but the differences were not
significant. Box-and-whiskers plot representing median (horizontal line within box), mean (diamond),
upper quartile, lower quartile, and range of values for TNN and TND by carrier group. I, initial
examination; F/U, follow-up examination (B12 years following initial examination).
Abbreviations: TND, total nevus density; TNN, total nevus number
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